Five cases of Kallmann's syndrome are presented, out-patients with microtestes, hypogonadotropic hypogonadism and complete anosmia. The ®nal diagnosis was made only when they were aged between 17 and 26 (mean 21 years), although they had been seen by several physicians before: 3 for cryptorchidism and 3 for absence of spontaneous puberty; 2 had a positive family history, and 4 of the 5 patients or their parents admitted that they were aware of the fact that their sense of smell was completely absent, but they did not mention it spontaneously.
Introduction
Hypogonadotropic patients may visit pediatricians, general practitioners, endocrinologists or urologists presenting with microphallus, cryptorchidism or pubertas tarda and delayed bone maturation. Congenital hypogonadotropic hypogonadism is characterized, apart from small testes, by the constellation of low serum levels of testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH). Kallmann's syndrome is characterized by congenital hypogonadotropic hypogonadism with midline defects such as anosmia (a de®ciency of the sense of smell). 1 The ®rst case report dates back to 1856, 2 and genetic defects causing the syndrome have been recently described. 3 The diagnosis can be clinically suspected and is established by con®rming hormonal studies.
Case reports

Case 1
A 26-y old man fell on his right hand. The X-ray of the wrist (Figure 1 ) not only demonstrated the fracture of the 5th metacarpus but also an open epiphyseal line, thus revealing markedly delayed bone age. The patient's voice has not broken and he reported weak erections. At the age of 3 y he underwent orchidopexy on the left side for cryptorchidism. He never had a girlfriend and was known as an obliging and courteous person. Physical examination shows eunuchoid proportions, decreased body hair with a female distribution and microphallus with a testicular volume of 2 ml on both sides. The patient did not smell offered coffee beans. Laboratory testing shows slight anemia (hemoglobin of 13.8 gadl) and low values of testosterone, FSH and LH (Table 1) , con®rming hypogonadotropic hypogonadism. LH and FSH increased promptly within 30 and 50 min in response to intravenous GnRH, consistent with normal pituitary function. Sperm analysis revealed cryptozoospermia. The magnetic resonance imaging (MRI) of the sella excluded a pituitary tumor. Hormonal replacement therapy with transdermal testosterone patches (Andropatch 1 ) brought serum testosterone levels and red blood cell indices (hemoglobin of 16.2 gadl) to values within the normal adult male range, and the voice of the patient changed 6 months later.
Case 2
A 24-y old patient consulted a general practitioner (the ®rst to address the problem of delayed puberty) for upper airway disease. He presented with an unbroken voice and sparse axillary and pubic body hair. He had a microphallus, testicular volumes of 2 ml and a bone age of 17 y. He did not smell garlic or curry. The sellar MRI was normal. Laboratory testing con®rms hypogonadotropic hypogonadism (Table 1) . After the ®rst injection of 125 mg testosterone enanthate, priapism occurred. After one year of testosterone therapy, normal male sex features and libido are reached. The patient does not wish to be fertile.
Case 3
A 17-y old male was referred by his family physician for suspected hypogonadism and with the differential diagnosis of constitutionally delayed puberty. He underwent human chorionic gonadotropin (hCG) cycles and ®nally a bilateral operation for maldescended testes when he was 8 y old. He had eunuchoid body proportions, a microphallus and a total lack of smell (remarkably, his sister is found to lack unilaterally the sense of smell and, later on, turns out to have primary amenorrhea, attributed to Kallmann's syndrome!). The laboratory values con®rmed the diagnosis of hypogonadotropic hypogonadism and LH increases in response to GnRH stimulation (Table 1) . Other pituitary functions are normal and so is MR imaging. The patient feels ®ne on testosterone replacement therapy, works as a farmer and is not yet married.
Case 4
An 18-y old male is bothered by his low physical performance and by being called Mrs on the phone. His mother reports that he underwent bilateral orchidopexy at the age of 8 y. He has small testicles (1 ml each) and has not yet entered puberty. His mother also noticed that he lacks the sense of smell, a ®nding con®rmed by neurological examination. Laboratory tests reveal low levels of total testosterone and gonadotropins (Table 1) . He is treated with testosterone enanthate injections (250 mg i.m. every 3 or 4 weeks) which leads to a full male phenotype, apart from the testes which remain small. He did not want peptide treatment to induce fertility.
Case 5
A shy 17-y old boy consulted (after discussing his problem with his father) his general practitioner for absence of spontaneous puberty and, later on, an urologist. He had long extremities and was taller than his father and brother, but had small testes (2 ml). Hemoglobin was low (11.6 gadl), and so was total testosterone (initially`0.1 nmolal), as expected. A diagnosis of Kleinfelter's syndrome was considered, but cytogenetic analysis revealed a normal male (46, XY) karyotype, and serum gonadotropins were low (Table 1) . He was treated with testosterone injections. Investigations 5 years later con®rmed hypogonadotropic hypogonadism, and moreover, showed an increase in LH in response to GnRH stimulation and complete anosmia. Family history revealed that his sister (who did not lack the sense of smell) had primary amenorrhea due to hypogonadotropic hypogonadism. She was initially treated with sex hormones and, later on, became pregnant after gonadotropin treatment for 2 years. Our patient would still like to receive peptide treatment for fertility induction, after planned marriage, if the treatment is reimbursed by his insurance. Clinical diagnosis of Kallmann's syndrome H John and C Schmid
Discussion
As shown by our ®ve case reports, Kallmann's syndrome is the most frequent cause of isolated gonadotropin de®ciency due to insuf®cient secretion of GnRH. In its classical form, this congenital syndrome results in the absence of endogenous GnRH-induced LH pulsations, often cryptorchidism and microphallus, and includes hyposmia or anosmia. Kallmann's syndrome affects 1 in 10 000 males; females are six times less frequently affected. The most frequent form of the autosomal recessive disease is linked to the X chromosome and appears to be due to a defect in the embryonic migration of GnRH neurons and olfactory axons from the nose to the brain. As shown by our four case reports, the diagnosis of Kallmann's syndrome is often made with substantial delay, despite clues in childhood such as anosmia, cryptorchidism and failure to enter puberty timely. Bone maturition and formation of longitudinal growth may occur at any age beyond 20 y. At presentation, concomitant de®cits of other pituitary hormones should be excluded by history, clinical examination and laboratory ®ndings. The differential diagnosis includes, apart from constitutionally delayed puberty, neoplastic and in¯amma-tory diseases but MRI imaging can rule out hypothalamic and pituitary tumors such as craniopharyngiomas or adenomas. Dynamic endocrine testing using intravenous GnRH will usually increase both LH and FSH.
The ®rst goal to achieve in therapy for hypogonadotropic hypogonadism is induction of puberty and, in males, virilization. Testosterone replacement therapy can be performed by intramuscular injections of testosterone esters or using transdermal testosterone patches. 4, 5 This treatment successfully substitutes for the lack of normal Leydig cell function but will not induce spermatogenesis.
Gonadotropin (hMG hCG) and pulsatile gonadotropin releasing hormone (GnRH) therapy are used to induce fertility. In patients with Kallmann's syndrome, GnRH is the treatment of choice, and GnRH may also work in other hypothalamic disorders, whereas in pituitary insuf®ciency, administration of gonadotropins (hMG (or rhFSH) hCG) is required. Adminstration of GnRH to GnRH-de®cient men simulates LH pulses observed in healthy men where pulses occur at a frequency of around 12 per day. Intravenous or subcutaneous administration of GnRH with an infusion pump delivering 2 ± 40 mg GnRH per pulse every 2 h was found to be effective in patients with Kallmann's syndrome. Spermatogenesis can be induced in the majority of these patients and fertility rates are above 50%. 6, 7 It may be dif®cult to estimate the prognosis for the individual, eg for patients with orchiopexy at an advanced age. The treatment by peptide hormones remains complicated and expensive but may be rewarding for those who can afford it and succeed in fathering children.
